Health Care/Hospital
111 to Announce Second Quarter 2023 Unaudited Financial Results on August 24, 2023 - Conference Call to Follow
SHANGHAI, July 31, 2023 /PRNewswire/ -- 111, Inc. (NASDAQ: YI) ("111" or the "Company"), a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services in China, today announced that it will report its unaudited financial result...
2023-07-31 17:59
1652
Biosion Announces Phase II Study Start for Anti-TSLP mAb BSI-045B in Atopic Dermatitis (ADAMANT)
NEWARK, N.J. and NANJING, China, July 31, 2023 /PRNewswire/ -- Biosion USA, Inc. (Biosion), a global clinical-stage R&D biotechnology company, today announced the phase 2 study initiation for the evaluation of BSI-045B, an anti-TLSP mAb, in the treatment of atopic dermatitis (AD) . "We are pleas...
2023-07-31 17:05
1533
GLOBAL SARCOMA THERAPY NOW LISTED ON PHARMACEUTICAL BENEFITS SCHEME
* YONDELIS® (trabectedin) now PBS listed for Australian patients * Listing described as "wonderful news" for patients living with rare lipo and leiomyo sarcomas * YONDELISÒ (trabectedin) demonstrates 45% reduction in risk of disease progression or death versus dacarbazine1 SINGAPORE, July 31...
2023-07-31 15:00
1674
U.S. FDA Accepts Biologics License Application for GC Biopharma's GC5107B (Immune Globulin Intravenous (Human), 10% Liquid)
YONGIN, South Korea, July 31, 2023 /PRNewswire/ -- GC Biopharma (006280.KS), a global biopharmaceutical company dedicated to specialty plasma-derived therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has accepted the Company's resubmission of the Biologics License App...
2023-07-31 13:20
1681
J INTS BIO, Novel Oral 4th Generation EGFR TKI 'JIN-A02' - Dosing of First Patient in the Global Multi-center Phase 1/2 Clinical Study began
SEOUL, South Korea, July 31, 2023 /PRNewswire/ -- J INTS BIO announced the
successful dosing of the first patient in its global multi-center Phase 1/2
clinical study of 'JIN-A02' on 31st July at Severance Hospital, Seoul, Korea.
2023-07-31 13:10
1335
Akeso Inc. Published 2023 Interim Results Positive Profit Alert
HONG KONG, July 31, 2023 /PRNewswire/ -- Akeso Inc. ("Akeso", the "Company"; 9926.HK), a commercial-stage biopharmaceutical company focused on developing and commercializing first-in-class and best-in-class innovative medicines globally, today announced that it is expected that the Company will r...
2023-07-31 12:33
3826
NMPA and FDA Approved the First-in-Human Clinical Trial Applications to Evaluate LBL-034, An Anti-GPRC5D/CD3 Bispecific Antibody Developed by Leads Biolabs, in Relapsed/Refractory Multiple Myeloma
NANJING, China, July 31, 2023 /PRNewswire/ -- Nanjing Leads Biolabs Co., Ltd. (hereinafter referred to as "Leads Biolabs" or "Company") announced today that the National Medical Products Administration (NMPA) and the U.S. Food and Drug Administration (FDA) have approved its first-in-human Investi...
2023-07-31 12:09
1257
VARON Reiterates Its Commitment to Brand Value and Its Determination to Reshape the Oxygen Concentrator Industry
SEATTLE, July 28, 2023 /PRNewswire/ -- VARON
2023-07-28 22:20
2585
Dr. Dapeng Liu: ChatGPT Redefines Medical Device As AI Medical Milestones
SHANGHAI, July 28, 2023 /PRNewswire/ -- In the ever-evolving world of AI, ChatGPT has emerged as a groundbreaking technology, capturing the attention of tech enthusiasts and industry experts alike. Within a short span of time, it has presented new challenges and opportunities for transformative c...
2023-07-28 21:20
2661
Derm Favorite Skincare Brand COSRX's Revenue Rises 138% YoY in the First Half of 2023
LOS ANGELES, July 28, 2023 /PRNewswire/ -- COSRX, a skincare brand favored by dermatologists, has recently revealed an impressive year-on-year growth of 138% in the first half of 2023. This remarkable achievement signifies an anticipated two-fold increase by the end of 2023, further reinforcing i...
2023-07-28 21:00
2983
Fresh2 Group Ltd. Completes Acquisition of SpeedIn INC, a Delivery Service Provider
NEW YORK, July 28, 2023 /PRNewswire/ -- Fresh2 Group Ltd., formerly AnPac Bio-Medical Science Co., Ltd. (NASDAQ: FRES) ("Fresh2," the "Company" or "we"), a company with operations inthe United States and China focused on the business-to-business e-commerce and supply chain sectors for the restaur...
2023-07-28 21:00
8065
HANQUYOU Marks 3rd Anniversary with Brilliant Achievements
* HANQUYOU is the China-developed biosimilar with the most marketing approvals, covering 41 countries and regions * The launch of HANQUYOU kicks off the competition between Chinese pharmaceutical companies and the world's bio-pharmaceutical companies in biosimilar monoclonal antibodies * He...
2023-07-28 15:27
2756
Wuan Ankang Hospital's Innovative Tumor Treatment Attracts Many Patients
HANDAN, China, July 28, 2023 /PRNewswire/ -- In Handan City, Hebei Province, China, the Wu'an Ankang Hospital has 35-year of experience with tumor treatment. It has now become a second-class general hospital. The reason it attracts many patients from bothChina and abroad is that they practice hol...
2023-07-28 14:35
1238
Empowering Regenerative Medicine: 3A-GTP Technology Ushers in a New Epoch
Pioneering Green Energy Solutions: DrSignal Biotech and J&V Energy's Promising Alliance TAIPEI, July 27, 2023 /PRNewswire/ -- At the 2022 Healthcare Expo Taiwan, Dr.Signal Biotech showcased the remarkable 3A-GTP technology, succeeding a significant breakthrough. This technology accelerates the p...
2023-07-28 10:00
1442
2023 Tsinghua Amgen Scholars Program Kicks Off
Continuing to Empower Young Scientists SHANGHAI, July 27, 2023 /PRNewswire/ -- Recently, 2023 Amgen Scholar Program (ASP) was opened inChina, partnering with Tsinghua University, one of China's top academic institutions and influential universities. 24 undergraduates were selected as Amgen Schol...
2023-07-27 21:00
1785
HanAll Biopharma Reports Second Quarter 2023 Financial Results and Provides a Business Update
* Sales recorded KRW 41.4 billion, a 58 percent increase from the same period in 2022, due to sustained robust growth of major products in addition to milestone revenues from the progress in clinical programs of batoclimab. * Multiple clinical development milestones have been reached, includin...
2023-07-27 19:00
1958
AI Medical Service Inc. Signs Joint Research Agreement with Stanford Medicine
- AIM Is First Japanese Company to Establish Joint Research Agreement in Field of Endoscopic AI - TOKYO, July 27, 2023 /PRNewswire/ -- AI Medical Service Inc. (hereinafter AIM), a medical start-up specializing in the development of diagnostic endoscopic AI, has signed a joint research agreement ...
2023-07-27 14:00
1238
GC Genome enables the prognosis prediction and targeted treatment in breast cancer patients
YONGIN, South Korea, July 26, 2023 /PRNewswire/ -- GC Genome Corporation, a leading genomic diagnostics company, announced the publication of a new study in Journal of the National Cancer Institute (JNCI), shedding light on the remarkable potential of utilizing circulating tumor DNA (ctDNA) copy n...
2023-07-27 08:53
1215
PharmAbcine Announces First Patient Dosed in the Phase I Clinical Trial of Its Novel TIE2 Agonistic Antibody in nAMD
DAEJEON, South Korea, July 26, 2023 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of next-generation antibody therapeutics, announced today that the first patient has been dosed in the Phase I clinical trial of PMC-403, the Compa...
2023-07-26 20:00
1657
Samsung Biologics Reports Second Quarter 2023 Financial Results
* Recorded Q2'23 consolidated revenue of KRW 866.2 billion * Recorded Q2'23 consolidated operating profit of KRW 253.4 billion * Achieved record-high semi-annual revenue exceeding KRW 1,587.1 billion * Strong growth sustained with successful contract wins and full completion of Plant 4 set ...
2023-07-26 15:23
1956
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 314 media titles]
2024-11-21 10:30Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 308 media titles]
2024-11-20 13:29Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 301 media titles]
2024-11-20 16:30
Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
[Picked up by 284 media titles]
2024-11-20 09:00
Most Read
Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
2024-11-20 16:30
7722
Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
2024-11-20 09:00
7116